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Abstract
Evidence about the role for reproductive and hormonal factors in the etiology of lung cancer in
women is conflicting. To clarify this question, we examined 407 female cases and 499 female
controls from the Environment And Genetics in Lung cancer Etiology (EAGLE) population-based
case-control study. Subjects were interviewed in person using a computer-assisted personal
interview to assess demographics, education, smoking history, medical history, occupational
history, reproductive and hormonal factors. Associations of interest were investigated using
logistic regression models, adjusted for catchment area and age (matching variables), cigarette
smoking (status, pack-years, and time since quitting). Additional confounding variables were
investigated but did not substantially affect the results. We observed a reduced risk of lung cancer
among women with later age at first live birth (≥31 years: OR=0.57, 95%CI=0.31–1.06, p-
trend=0.05), later age at menopause (≥51 years: OR=0.49, 95%CI=0.31–0.79, p-trend=0.003), and
longer reproductive periods (≥41 years: OR=0.44, 95%CI=0.25–0.79, p-trend=0.01). A reduced
risk was also observed for Hormone Replacement Therapy (OR=0.63, 95%CI=0.42–0.95, p=0.03)
and oral contraceptive use (OR=0.67, 95%CI=0.45–1.00, p=0.05), but no trend with duration of
use was detected. Menopausal status (both natural and induced) was associated with an augmented
risk. No additional associations were identified for other reproductive variables. This study
suggests that women who continue to produce estrogens have a lower lung cancer risk. Large
studies with great number of never smoking women, biomarkers of estrogen and molecular
classification of lung cancer are needed for a more comprehensive view of the association between
reproductive factors and lung cancer risk.
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INTRODUCTION
Lung cancer is the leading cause of cancer mortality worldwide. In the last three decades, its
risk is dramatically increased in women, for whom is the fourth most common tumor
(513,000 cases, 8.5% of all cancers) and the second in number of deaths (427,000 deaths,
12.8% of the total). 1 In contrast, the risk has leveled off or decreased in men. Although
different patterns of cigarette smoking over time between the two sexes is likely to account
for most of the difference, the hypothesis of a higher female susceptibility to tobacco-related
lung cancer has emerged, with conflicting epidemiological results. 2 Still, there is consensus
that important biological differences between the sexes exist in non-small-lung cancer risk.
In particular, women are more likely to develop adenocarcinomas, and experience younger
age at onset. 3 Moreover, a reduced DNA repair capacity has been showed in females tumors
compared to men and the hypothesis that estrogens can play a role in lung cancer
carcinogenesis has gained attention. 4 Estrogen effects are likely to be mediated by the
estrogen receptors (ER) α and β. ERα mRNA are expressed at low levels in the lung,
whereas ERβ, the less active in inducing transcriptional activation, has been shown to be
expressed in both normal and tumor pulmonary tissue.5–7 Estrogens could also interact with
cigarette smoking by accelerating the metabolism of smoking derived carcinogens.8
The first clue of a potential role for estrogens and reproductive factors came from a study of
women in China that showed increased lung cancer risk with shorter menstrual cycle
length.9 Afterwards, numerous observational studies examined the relationship between lung
cancer and reproductive factors including: parity, age at first live birth, age at menarche, and
age at menopause.10–25 However the findings across studies are far from being consistent.
Most studies are small and examined only a few reproductive factors. The three most recent
cohort studies, the Shanghai Women’s Health Study.19 the Nurses’ Health Study,24 and the
NIH-AARP Diet and Health Study,10 suggested a possible protective role of endogenous
estrogens showing reduced lung cancer risk with later age at menopause10,19,24 and longer
reproductive periods.19
In a small hospital-based case-control study, Taioli and Wynder 18, showed a positive
association between hormone replacement therapy (HRT) and risk of lung cancer, but most
subsequent case-control12,14,15,26–30 and cohort studies10,11,13,16,19,24,31–35 did not support
this hypothesis. Also investigations on oral contraceptive (OC) use and lung cancer risk
failed to show a clear association.11,12,14–16,18,19,24,28,36,37
The purpose of our study was to examine whether reproductive or hormonal factors are
associated with the risk of lung cancer in a population-based case-control study conducted in
Italy, with a relatively large number of female cases and population controls.
MATERIAL AND METHODS
Study population
EAGLE (Environment And Genetics in Lung cancer Etiology) is a population based case-
control study primarily designed to investigate the genetic and environmental determinants
of lung cancer. The study protocol has been extensively described elsewhere.38 Incident
lung cancer cases (2,100) and 2,120 population controls were enrolled between 2002 and
2005 from a catchment area including 216 municipalities in the Lombardy region of Italy.
Lung cancer cases were enrolled in 13 hospitals and population controls were randomly
sampled from the catchment area to frequency match the cases by residence, gender, and
age. Subjects were 35–79 years at diagnosis or at sampling. Participation rates were 86.6%
for cases and 72.4% for controls. Extensive clinical data were collected for lung cancer
cases including morphology coded according to the International Classification of Diseases
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for Oncology, Third Edition.39 The study was approved by the institutional review boards
and all participants signed a written informed consent. Our study population includes the
EAGLE females study subjects (448 cases and 500 controls).
Exposure assessment
All cases and controls underwent a Computer Assisted Personal Interview and completed a
self-administered questionnaire (both questionnaires are available on the EAGLE website
(http://eagle.cancer.gov/). The interview included questions on demographics, education,
current and past smoking behavior, environmental tobacco smoke (ETS) at home (during
childhood and adulthood) and at the workplace, alcohol consumption, medical history,
family history of cancer and occupational history. For women, the questionnaire also
included a detailed section on reproductive history. Information on age at menarche, age at
menopause, average length of menstrual cycle, age at first pregnancy, number of full term
pregnancies, breast-feeding, and history of ovariectomy, and use of oral contraceptives (OC)
was recorded. Menopausal women were asked on the type of menopause (natural, or
induced by surgery, radiation or chemotherapy), on age at start and duration, and on use of
hormone replacement therapy (HRT). No information was collected on type of hormones or
dosage. The self-administered questionnaire investigated behavioral aspects related to
smoking habits and diet.
Statistical analyses
Odds ratios (ORs), 95% confidence intervals (CI), and tests for trend were calculated using
unconditional logistic regression. All models included the matching variables: area (five
categories including 5 large cities and their surrounding municipalities) and age (five-year
categories). Additional potential confounders or effect modifiers examined in the models
were: smoking status (ever/never); pack-years (continuous, mean-centered: linear, quadratic,
and cubic terms); time since quitting (0 for never/current smokers, 0.5, 1, 2, 5, 10, 20, ≥30
years),40 education, body mass index (BMI), and environmental tobacco smoke (ETS) at
home (during childhood and/or adulthood) and at work. Risk estimates were little affected
by the inclusion of other covariates such as alcohol consumption, occupational exposure to
lung carcinogens, personal history of other cancers, and family history of lung cancer, so
they were not included in the final model.
Several reproductive characteristics were investigated as independent variables: age at
menarche (<13, 13–14, ≥15 years), cycle duration (<27, 27–28, ≥29 days), parity (0, 1, 2, ≥3
live-births), age at first live-birth (<22, 22–25, 26–30, ≥31 years), breastfeeding (ever/
never), menopausal status (no, natural menopause, induced menopause), age at menopause
(<46, 46–50, ≥51 years), ovariectomy (both ovaries removed yes/no), oral contraceptives
(OC) and hormone replacement therapy (HRT) (ever, never, and duration of use in years).
We also calculated duration of the reproductive period – time from age at menarche to age at
menopause (if in menopause) or from age at menarche to age at diagnosis/enrollment (if not
in menopause) – and duration of menopause – time between age at menopause and age at
diagnosis/enrollment.
When adequate, we also ran all models including the independent variables as continuous.
To evaluate interaction between reproductive variables and smoking or BMI, we compared
the log-likelihood of models with and without product terms.
Multinomial logistic regression models were performed to test the homogeneity of the
association between reproductive variables and lung cancer risk across histological types.
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All tests were two-sided. Statistical analyses were performed using Stata 11 (Stata
Corporation, College Station, TX).
RESULTS
Out of 448 female cases and 500 female controls enrolled in the study, interviews or
questionnaire information were available for 407 cases (90.8%) and 499 controls (99.8%)
(Table 1). Cases and controls did not differ for residential area, and age (the effect of
matching), education, environmental tobacco smoke, or alcohol consumption, and
occupational exposure to known (list A) or suspected (list B) lung carcinogens according to
the International Agency for Research on Cancer (IARC) evaluations.40 Almost half of the
cases (46%) were current smokers compared with 21% of the controls; cases had smoked a
greater number of cigarettes. The proportion of subjects underweight was higher among
cases and that of obese higher in controls. Cases had a higher frequency of primary cancer
other than lung cancer and reported more frequently a positive family history of lung cancer.
As expected, the majority of lung cancers were adenocarcinomas.
Table 2 shows associations between lung cancer and each exposure variable. After adjusting
for area, age and smoking, reduced risk of lung cancer was observed among women with
later age at first live birth (OR=0.57; 95% CI 0.31–1.06 for ≥31 vs. <22 years, p-
trend=0.05), later age at menopause (OR=0.49; 95% CI 0.31–0.79 for ≥51 vs. <46 years, p-
trend=0.003), and longer reproductive duration (OR=0.44; 95% CI 0.25–0.79 for ≥41 vs.
<33 years, p-trend=0.01). Menopausal status (both natural and induced) was associated with
an augmented risk which increased with menopause duration (p-trend=0.002); exclusion of
women who declared to be in surgical menopause but not to have undergone bilateral
ovariectomy (thus, potentially, maintaining their ovarian function unaltered) did not
substantially modify the effect estimates (i.e. about 5%, data not shown).
Hormone replacement therapy and the use of oral contraceptives were associated with a
reduced lung cancer risk (OR=0.63; 95% CI: 0.42–0.95 and OR=0.67; 95 CI%: 0.45–1.00,
respectively). The risk did not substantially change among women with longer duration of
HRT or OC use.
Lung cancer risk was not associated with age at menarche, cycle duration, breastfeeding and
parity.
Further adjustment for passive smoking, education, and BMI did not substantially change
the risk estimates of each exposure variable.
We also examined the results separately for never and ever smokers (current and former)
and we found no evidence of interaction between the reproductive variables and smoking
status. Although based on small numbers, the direction of the associations was similar in the
two groups for most of the examined variables (Table S1; Supplementary).
Since the residual sources of estrogen production in menopausal women are related to the
production of estrone from androstenedione in adipose tissue, the risks for menopause status
and menopause duration were separately examined for women with BMI < 25 and ≥ 25. OR
estimates did not differ (p for interaction = 0.68 and 0.93, respectively; Table S2;
Supplementary)
We also examined the increasing risk of lung cancer with menopause duration separately in
never and ever users of HRT: the pattern of increasing risk did not differ (p for interaction =
0.33; Table S3; Supplementary). In the same way, when we considered lung cancer risk for
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reproductive duration stratified by OC use (ever, never) a similar decreasing risk was
observed in the two groups (p for interaction =0.79).
Similar OR patterns were observed across histological types (adenocarcinoma versus other
morphologies, Table 3).
DISCUSSION
In a population-based case-control study conducted in Italy (EAGLE), endogenous
hormones during premenopausal years appear to have a protective role in lung cancer
development. Specifically, we found a reduced risk of lung cancer with later age at
menopause (and, correspondingly, increasing risk with menopause), later age at first live
birth and longer reproductive period. These findings were consistent across the major lung
cancer histology groups. In contrast, lung cancer risk was not associated with age at
menarche, cycle duration, breastfeeding or parity. These findings suggest a complex pattern
of hormone-related factors in association with lung cancer risk.
Our results on the protective effect of later menopause or longer reproductive periods,
support previous findings from large prospective studies (the Nurses’ Health study and the
NIH-AARP Diet and Health Study, respectively),24,10 which found increased risk of lung
cancer with younger age at menopause. Similarly, a prospective study in lifetime
nonsmokers Chinese women showed an inverse association between age at menopause and
the risk of lung cancer.19 Similar results, although not statistically significant, were observed
in three case-control studies from Canada,25 Czechoslovakia,21 and China.41 However, other
studies showed positive associations with lung cancer risk9,18,20,22 or null results.12–16
Age at first live birth was not associated with lung cancer risk in most studies.13–15,17–19,25
A few 2422 reported an increased risk with older age at first live birth, while others 11,12
reported an inverse association.
The only study which examined the length of the reproductive period19 showed a pattern
consistent with ours.
The use of OC and HRT in our population was associated with a reduced lung cancer risk,
however no trend in risk was found with increasing duration of use. Observational studies
that investigated the association between HRT and lung cancer risk have shown mixed
results. After the increased risk reported by Taioli et al.18, only one study found a doubled
risk limited to induced menopausal women treated with HRT.13 No effect,11,14,16,19,24,28,33
or reduced risk were found in other studies.12,15,29,30,34,42 A recent review of 18 studies (15
observational studies and 3 randomized clinical trials) found mixed results,43 however the
authors cautioned the interpretation of these findings since most studies did not report
smoking status and HRT type. The findings of another meta-analysis of 11 studies published
between 1968 and April 2008 (8 case-control studies and 3 cohort studies)44 do not support
the hypothesis of an association between HRT and lung cancer risk. Slatore et al.35
examined a large cohort of menopausal women and found that the use of combined
(estrogen + progestin) hormone therapy was associated with an increased risk of lung cancer
in a duration-dependent manner with a 50% increase in women using HRT for a period
longer than ten years. In the Women’s Health Initiative randomized controlled trial study,
the use of estrogen alone was not associated with increased incidence or mortality from lung
cancer32 whereas estrogen plus progestin therapy was associated with an increased
mortality, but not incidence, from lung cancer.31 In our study population we did not collect
information on HRT type and therefore cannot address this issue.
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With regard to oral contraceptive use, most observational studies found no association with
lung cancer risk.11,14–16,18,19,24,28 Kreuzer et al.12 observed a reduction in lung cancer risk,
but no trend in risk with increasing duration as in our study. On the contrary, in the Nurses’
Health Study24 duration of OC use longer than 5 years was associated with a slightly
increased risk. Two other large cohort studies in UK, the Royal College of General
Practitioners cohort study and the Oxford FPA cohort study, compared long-term mortality
in ever versus never-users of OC and did not find major differences across the two
groups.36,37
We found no association with cycle duration, breastfeeding or parity. These findings appear
in contrast with the quite consistent pattern of an inverse association of estrogen-related
variables with lung cancer risk in our study. A possible explanation is that reproductive
factors may not be consistently associated with estrogen levels. A recent study in
premenopausal women reported no association between 15 different estrogens measured in
the urine and age at menarche, OC use, parity, or breastfeeding 45, but showed a significant
association with menstrual cycle length and regularity and age at first birth. This suggests a
complex association between estrogen levels and reproductive factors. Moreover, the effects
of these hormones are likely to be tissue-specific, as the different patterns of association
between breast and lung cancer risk seem to indicate46.
Studies on the role of estrogen receptor (ER) expression in lung cancer have been
inconclusive with high levels of ER expression in some studies, but very low levels in
others.47,48 Schwartz et al.15 found that postmenopausal hormone use was associated with
reduced lung cancer risk only in non-small cell lung cancers characterized as ER α and/or β
positive. In addition, Chleboswski et al.32 hypothesized that the stimulation of estrogen
receptor alone is not sufficient to increase lung cancer growth but stimulation of
progesterone receptor is also needed. Additional evidences suggest that estrogens can
interact with growth factors, in particular Epidermal Growth Factor (EGF). Although EGF is
known to be involved in cell growth, protection from apoptosis and angiogenesis, it is
possible that ER and EGF pathways are alternatively activated, since EGFR protein
expression was shown to be down-regulated in response to estrogens.49 It is also possible
that specific subgroups of lung cancer may be differentially associated with estrogens, as it
appears for ER positive vs. ER negative or basal-like breast cancer types. 50 Our results
were consistent across histology groups of lung cancer, but more subtle, molecularly-related
subgroups may be present and account for some of these differences.
Moreover, different study designs, modest sample sizes, and populations with different
ethnicities, life styles, diet or proportion of smokers could have contributed to the disparate
findings across the studies. Our study is a population-based case-control investigation
conducted in Caucasians, with life style and diet typical of a Western population.
Confounding by smoking is often raised as a possible explanation of the inconsistent
findings. Although the analyses in never smoking women in our study were limited by the
small sample size, EAGLE benefitted from comprehensive and detailed data on smoking,
which allowed for tight adjustment by smoking status, intensity, duration and time since
quitting. Although residual confounding by smoking can never be completely ruled out, it is
unlikely that smoking can substantially explain our results.
Additional strengths of our study were a quite large sample size as a whole, the high
participation rates, which reduces the likelihood of selection bias, and the detailed and
comprehensive assessment of reproductive factors and major confounding variables. Study
limitations include lack of data on hormone therapy type. In addition, analyses by smoking
status were limited by the small number of cases in each category.
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In conclusion, in a population-based study of lung cancer, we found that women who
continue to produce endogenous hormones have a lower lung cancer risk. Larger studies (or
pooled datasets) with rigorously defined reproductive variables, large number of never
smoking women, biomarkers of estrogen and molecular classification of lung cancer are
needed for a more comprehensive view of the association between reproductive factors and
lung cancer risk.
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Novelty and impact of the work
The EAGLE population-based case-control study finds a consistent pattern of reduced
lung cancer risk among women with later age at first live birth, at menopause, and longer
reproductive period. Together with recent reports from large cohort studies, our study
supports that women who continue to produce estrogens have a lower lung cancer risk.
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